According to the news released by CSRC (China Securities Regulatory Commission) on August 31, CSRC has approved the registration of the following companies for initial public offering of shares on the board in accordance with the statutory procedures: Beijing FJR Optoelectronic Technology, Beijing Tongyizhong New Material Technology and JJE Electronic Technology. The above companies and their underwriters will negotiate with the Shanghai Stock Exchange to determine the issuance schedule and publish the prospectus documents.

Several days ago, the Ministry of Industry and Information Technology announced the “List of National Specialized and New “Small Giant” Enterprises Recommended for Support (Second Batch, First Year)”, Beijing Tongyizhong New Material Technology is in the list. Thus, we can conclude that it is a company with high strength.

Beijing Tongyizhong New Material Technology was established in 1999. It is a national high-tech enterprise specializing in the R&D, production and sales of UHMWPE fiber and related compounding materials. It is one of the first enterprises in China to fully master the UHMWPE fiber technology and realize the industrialization of UHMWPE fiber.

Its main products include UHMWPE fiber and related compounding materials. Among which the compounding materials are divided into two categories: weftless cloth and bulletproof products. UHMWPE fiber is the main raw material used to produce the weftless cloth. The company also produces bulletproof products on the basis of weftless cloth by using specific technology and materials

In 2000, Beijing Tongyizhong became one of the first enterprises realizing the industrialization of UHMWPE fiber in China

In 2012, Beijing Tongyizhong was relocated to the National High Technology Industrialization Demonstration Project Base, achieving an UHMWPE fiber output of 550 MT. The 4th generation of UHMWPE fiber production line was put into operation.

Source: CSRC (China Securities Regulatory Commission), Beijing Tongyizhong

Previous PostNext Post
Please contact HCA for further information